Drug
Adafosbuvir clinical trials
Also written AL-335 and JNJ-64146212.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
10 studies that test it; most in 2016 (6)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Janssen Research & Development, LLC (7) · Alios Biopharma Inc. (2) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Odalasvir (6) · Simeprevir (5) · ODV 200 (1) · ODV 125 (1) · ODV 100 (1) · Drospirenone (1) · Ethinyl Estradiol (1)
Studies
Open first, then newest update. How each study uses adafosbuvir is read from its arms, and is right about nine times in ten.
Testing it · 10
- Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02824315Written as AL-335
- Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C InfectionCompletedPhase 2Janssen Research & Development, LLCNCT02765490Written as AL-335
- A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy VolunteersCompletedPhase 1Alios Biopharma Inc.NCT02512562Written as AL-335
- First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedPhase 1Alios Biopharma Inc.NCT02339207Written as AL-335
- A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveCompletedPhase 2Janssen Pharmaceutical K.K.NCT02993250Written as AL-335
- Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02821858Written as AL-335
- A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335CompletedPhase 1Janssen Research & Development, LLCNCT02894905Written as AL-335
- A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT03155893Written as AL-335 1200 mg
- A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic FunctionWithdrawnPhase 1Janssen Research & Development, LLCNCT03277755Written as AL-335 800 mg
- To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02885454Written as AL-335
Given in every arm · 2 — adafosbuvir is usual care beside what is tested
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and SimeprevirCompletedPhase 2Alios Biopharma Inc.NCT02569710Written as AL-335
- Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)TerminatedPhase 1Janssen Research & Development, LLCNCT03059303Written as AL-335 800 mg
Codes
What other systems call adafosbuvir · ClinicalTrials.gg INT001024
- MeSH (NLM) C000629483adafosbuvirOne source NLM
- UNII (FDA) S83770Y75RADAFOSBUVIRConfirmed FDA, NLM
- NCI Thesaurus C169763AdafosbuvirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629483 | adafosbuvir | One source NLM |
| UNII (FDA) | S83770Y75R | ADAFOSBUVIR | Confirmed FDA, NLM |
| NCI Thesaurus | C169763 | Adafosbuvir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.